Clase Neera reported grant involving 6,678 derivative units of Tarsus Pharmaceuticals, Inc. at $0.00 for $0 on Nov 3, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Commercial Officer
Chief Commercial Officer
Filed Nov 5, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
6,678Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
6,678Direct
Trade date
Nov 3, 2026Grant
Filed
Nov 5, 2026, 4:40 PM ET2-day reporting delay
Accession
0002162845-26-000005Code A · Transaction 393633
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 3, 2026Grant10,587$0.00$0Trade 393632
2 transaction rows in this filing. Joint filers share the same rows.

TARS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TARS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +3.2%1w ago 0%1d ago 0%
Returns since7d +8.7%30d90d180d1y

Footnotes in full

F1: 25% of the option shares shall vest on November 1, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: The RSUs will vest in four equal annual installments on December 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.